Table 2. G6PD variants identified in patients enrolled into the study.
| Afghanistan | Ethiopia* | Indonesia | Vietnam | Total | |
|---|---|---|---|---|---|
| N = 6 | N = 5 | N = 19 | N = 20 | N = 50 | |
| 357A-G | 3 (60.0%) | 3 (6.0%) | |||
| Asahri (AF1) | 1 (20.0%) | 1 (2.0%) | |||
| Canton | 2 (10.0%) | 2 (4.0%) | |||
| Chatham | 1 (5.3%) | 1 (2.0%) | |||
| Gaohe | 1 (5.0%) | 1 (2.0%) | |||
| Kaiping | 2 (10.0%) | 2 (4.0%) | |||
| Ludhiana | 1 (16.7%) | 1 (2.0%) | |||
| Mediterranean | 4 (66.7%) | 4 (8.0%) | |||
| Orissa | 1 (5.3%) | 1 (2.0%) | |||
| Viangchan | 3 (15.8%) | 11 (55.0%) | 14 (28.0%) | ||
| Vanua Lava | 1 (5.3%) | 1 (2.0%) | |||
| Confirmed G6PDd | 5 (83.3%) | 4 (80.0%) | 6 (31.6%) | 16 (80%) | 31 (62.0%) |
| Hemizygous males | 5 | 4 | 4 | 13 | 26 |
| Heterozygous females | 0 | 0 | 2 | 3 | 5 |
| Unconfirmed | 1 (16.7%) | 1 (20.0%)* | 13 (68.4%) | 4 (20.0%) | 19 (38.0%) |
*1 male in Ethiopia genotyped as AF2 (202G>A) and was categorized as A+ and not confirmed as deficient. Enzyme activities are presented in S1 Data.